KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)

Data as of 3:59pm ET
 +0.01 / +0.55%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of monoclonal antibody therapeutics. It develops a portfolio of proprietary and patient-targeted monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer. The company's antibody technology, Humaneered, treats serious medical conditions with a primary clinical focus on respiratory diseases and cancer. KaloBios Pharmaceuticals was founded on March 15, 2000 and is headquartered in South San Francisco, CA.

Contact Information

KaloBios Pharmaceuticals, Inc.
260 East Grand Avenue
South San Francisco California 94080
P:(650) 243-3100
Investor Relations:



Individual stakeholders31.85%
Other institutional29.10%
Mutual fund holders24.21%

Top Executives

David W. PritchardPresident, Chief Executive Officer & Director
Herbert C. CrossChief Financial Officer
Geoffrey Thomas YarrantonCSO, Executive VP-Research & Development
NĂ©stor A. MolfinoChief Medical Officer
Harry LamSenior Vice President-Technical Operations

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.